FASEB SRC: The Consequences of Aneuploidy: Honoring the Contributions of Angelika Amon
FASEB SRC: The Consequences of Aneuploidy: Honoring the Contributions of Angelika Amon
批准号:
10467260
负责人:
Jason Sheltzer
金额:
$3.5万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-13 至 2023-08-31
关键词:
AddressAmericanAneuploid CellsAneuploidyAreaAutomobile DrivingBiologyCellsChildChromosomal InstabilityChromosome SegregationChromosomesClinicalComplementDNA Sequence AlterationDevelopmentDiseaseDown SyndromeDrug resistanceEventExhibitsExtinction (Psychology)FriendsFundingGenesGeneticGoalsGrantGrowthHaploidyHealthHumanHusbandIndividualIntellectual functioning disabilityInternationalLogisticsMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of ovaryMassachusettsMemoryOrganismPatient-Focused OutcomesPhysiologyResearchResearch PersonnelScienceScientistSecureSeriesSocietiesStressUnited StatesWidowhoodbasecareercareer developmentchromosome missegregationcostdosageexperiencememberoutreachpostersprofessorsymposiumtumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
We are requesting grant support for a new FASEB conference entitled “The Consequences of Aneuploidy:
Honoring the Contributions of Angelika Amon.” This conference will be held from September 11th to 16th, 2022,
in Southbridge, Massachusetts. The broad goals for this conference are two-fold: first, to bring together the
world’s leading experts in studying the consequences of aneuploidy, and second, to honor the contributions of
Angelika Amon, a pioneer of aneuploidy research who passed away from ovarian cancer in 2020.
Aneuploidy, or a chromosome copy number state that is not a whole-number multiple of an organism’s normal
haploid complement, is a hallmark of malignant growth and is the most common genetic cause of intellectual
disability. Current sequencing-based estimates suggest that up to 90% of human tumors exhibit aneuploidy, and
high levels of aneuploidy are associated with metastatic disease, drug resistance, and dismal patient outcomes.
Despite the ubiquity of aneuploidy in cancer and its significance to human health, there are no regular
conferences in the United States dedicated to sharing the latest advances on this class of genomic alterations.
We aim to establish a new conference on this topic that will serve as a forum to bring together scientists to share
the latest advances in this exciting and fast-moving field. The organizing team for this conference consists of
leading aneuploidy researchers who were Angelika’s colleagues and trainees and are convening this inaugural
conference in her memory. This team has already secured the support of FASEB for this conference, which will
provide significant organizational, logistic, and technical support for the event. R13 grant funding is being
requested to subsidize the costs for early-career researchers and researchers from under-represented
backgrounds to attend this event. We currently have 41 confirmed speakers across 10 topic areas related to
aneuploidy and chromosome segregation, with a particular focus on the impact of aneuploidy on tumor
development and human health. Additional programming is planned for early-career scientists, including a series
of short talks, two poster sessions, and several career-development events.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genomic and functional approaches to characterize Chr1q gains in cancer
-
批准号:10567006
-
项目类别:
-
资助金额:$53.3万
-
财政年份:2023
-
负责人:Jason Sheltzer
-
依托单位:
Discovering the mechanisms of-action-mistargeted anti-cancer agents
-
批准号:10390462
-
项目类别:
-
资助金额:$22.04万
-
财政年份:2020
-
负责人:Jason Sheltzer
-
依托单位:
Discovering the mechanisms of-action-mistargeted anti-cancer agents
-
批准号:10533110
-
项目类别:
-
资助金额:$14.6万
-
财政年份:2020
-
负责人:Jason Sheltzer
-
依托单位:
Discovering the mechanisms of-action-mistargeted anti-cancer agents
-
批准号:10759016
-
项目类别:
-
资助金额:$14.31万
-
财政年份:2020
-
负责人:Jason Sheltzer
-
依托单位:
Discovering the mechanisms of-action-mistargeted anti-cancer agents
-
批准号:10668942
-
项目类别:
-
资助金额:$23.02万
-
财政年份:2020
-
负责人:Jason Sheltzer
-
依托单位:
Discovering the mechanisms-of-action of mistargeted anti-cancer agents
-
批准号:9886861
-
项目类别:
-
资助金额:$26.93万
-
财政年份:2020
-
负责人:Jason Sheltzer
-
依托单位:
Identification and characterization of genomic features affecting survival duration in cancer
-
批准号:9146424
-
项目类别:
-
资助金额:$47.08万
-
财政年份:2015
-
负责人:Jason Sheltzer
-
依托单位:
Identification and characterization of genomic features affecting survival duration in cancer
-
批准号:10063482
-
项目类别:
-
资助金额:$48.0万
-
财政年份:2015
-
负责人:Jason Sheltzer
-
依托单位:
海外基金